Hepatitis C virus NS3 inhibitors: current and future perspectives

Area of Science:

• Virology
• Hepatology
• Drug Discovery

Background:

• Hepatitis C virus (HCV) infection remains a significant global health concern.
• Direct-acting antivirals (DAAs) have advanced HCV treatment, with approved NS3-4A protease inhibitors showing improved sustained virologic response (SVR).
• Current therapies face challenges including adverse effects and the emergence of viral resistance.

Purpose of the Study:

• To review current understanding of HCV treatment strategies.
• To highlight the potential of the NS3 protein's helicase portion as an underdeveloped therapeutic target.
• To focus on the development and application of NS3 inhibitors for HCV infection.

Main Methods:

• Literature review of current HCV treatments.
• Analysis of direct-acting antiviral mechanisms and clinical progress.
• Examination of viral resistance patterns and therapeutic targets.

Main Results:

• Approved NS3-4A protease inhibitors (telaprevir, boceprevir) combined with standard care improve SVR.
• Adverse effects and viral resistance remain significant concerns with current therapies.
• The NS3 helicase is identified as a promising, yet underdeveloped, target for novel HCV inhibitors.

Conclusions:

• While DAAs have improved HCV treatment, challenges necessitate the development of new therapeutic strategies.
• NS3 inhibitors, especially those targeting the helicase domain, hold potential for overcoming resistance and improving treatment efficacy.
• Further research into NS3 helicase inhibitors is crucial for advancing hepatitis C therapy.